Evaluating the Effect of Cabergoline on Glycaemic Control of Patients with Type 2 Diabetes Mellitus: A Randomised Controlled Trial
Introduction: Although bromocriptine has been approved as an antidiabetic agent, few studies have reported the beneficial effects of other anti-hyperglycemic long acting dopamine agonist agents. In this regard, Cabergoline has fewer side-effects than that of Bromocriptine which can be administered a...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2020-02-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://www.jcdr.net/articles/PDF/13481/43034_CE[Ra1]_F(SL)_PF1(AJ_KM)_GC(Su_KM)_PN(SL).pdf |